Brogidirsen (NS-089/NCNP-02) 5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 World Muscle Society Congress

PARAMUS, N.J., Oct. 1, 2026 /PRNewswire/ -- NS Pharma, Inc. (Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama), a biopharmaceutical leader in rare disease and subsidiary of Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Toru Nakai), announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki Nakagome) presented 5-year efficacy and safety data from the open-label extension of an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy (DMD) at the 31^st annual International Congress of the World Muscle Society held in Hiroshima, Japan from September 29 to October 3, 2026.